Crowther Caroline A, Doyle Lex W, Haslam Ross R, Hiller Janet E, Harding Jane E, Robinson Jeffrey S
Disciplines of Obstetrics and Gynaecology, University of Adelaide, Women's and Children's Hospital, Adelaide, Australia.
N Engl J Med. 2007 Sep 20;357(12):1179-89. doi: 10.1056/NEJMoa071152.
We previously reported the results of a randomized, controlled trial showing that repeat doses of antenatal corticosteroids reduced the risk of respiratory distress syndrome and serious neonatal morbidity. However, data have not been available regarding longer-term effects of this treatment.
Women who had received an initial course of corticosteroid treatment 7 or more days previously were randomly assigned to receive an intramuscular injection of corticosteroid (11.4 mg of betamethasone) or saline placebo; the dose was repeated weekly if the mother was still considered to be at risk for preterm delivery and the duration of gestation was less than 32 weeks. We assessed survival free of major neurosensory disability and body size of the children at 2 years of corrected age.
Of the 1085 children who were alive at 2 years of age, 1047 (96.5%) were seen for assessment (521 exposed to repeat-corticosteroid treatment and 526 exposed to placebo). The rate of survival free of major disability was similar in the repeat-corticosteroid and placebo groups (84.4% and 81.0%, respectively; adjusted relative risk, 1.04, 95% confidence interval, 0.98 to 1.10; adjusted P=0.20). There were no significant differences between the groups in body size, blood pressure, use of health services, respiratory morbidity, or child behavior scores, although children exposed to repeat doses of corticosteroids were more likely than those exposed to placebo to warrant assessment for attention problems (P=0.04).
Administration of repeat doses of antenatal corticosteroids reduces neonatal morbidity without changing either survival free of major neurosensory disability or body size at 2 years of age. (Current Controlled Trials number, ISRCTN48656428 [controlled-trials.com].).
我们之前报告了一项随机对照试验的结果,该试验表明重复剂量的产前皮质类固醇可降低呼吸窘迫综合征和严重新生儿发病的风险。然而,关于这种治疗的长期影响的数据尚未可得。
在7天或更早之前接受过初始疗程皮质类固醇治疗的女性被随机分配接受肌肉注射皮质类固醇(11.4毫克倍他米松)或生理盐水安慰剂;如果母亲仍被认为有早产风险且孕周小于32周,则每周重复给药一次。我们在矫正年龄2岁时评估了儿童无重大神经感觉残疾的生存率和身体大小。
在2岁时存活的1085名儿童中,1047名(96.5%)接受了评估(521名接受重复皮质类固醇治疗,526名接受安慰剂治疗)。重复皮质类固醇组和安慰剂组无重大残疾的生存率相似(分别为84.4%和81.0%;调整后的相对风险为1.04,95%置信区间为0.98至1.10;调整后的P=0.20)。两组在身体大小、血压、医疗服务使用、呼吸系统发病率或儿童行为评分方面没有显著差异,尽管接受重复剂量皮质类固醇治疗的儿童比接受安慰剂治疗的儿童更有可能需要接受注意力问题评估(P=0.04)。
重复剂量的产前皮质类固醇给药可降低新生儿发病率,而不会改变2岁时无重大神经感觉残疾的生存率或身体大小。(当前对照试验编号,ISRCTN48656428 [controlled-trials.com]。)